Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Early Ablation Therapy for the Treatment of Ischemic Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillators

Study:

Early Ablation Therapy for the Treatment of Ischemic Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillators

Rationale:

n/a

Purpose:

The purpose of this study is to determine if early ablation (i.e., ablation of ventricular tachycardia in patients with infrequent VT episodes) is more effective than medical therapy alone for the treatment of ischemic ventricular tachycardia in patients with Implantable Cardioverter Defibrillators (ICDs) who continue to have episodes of ventricular tachycardia despite drug therapy.

Study Status: Recruiting

Recruiting:
Melanie Panko, RN 216-444-6478 pankom@ccf.org

Condition Intervention Phase
Ventricular Tachycardia
Ischemic
Drug: Drug Treatment
Device: Catheter Ablation
Phase 4

Verified by Biosense Webster, Inc. November, 2013

Sponsored by: Biosense Webster, Inc.
Information provided by: Biosense Webster, Inc.
ClinicalTrials.gov identifier: NCT01557842

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

David Callans, MD., Study Chair
Francis Marchlinski, MD., Study Chair
Andrea Natale, MD., Study Chair
Vivek Reddy, MD., Study Chair
David Wilber, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site